Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Enrollment commences in Allos' FOLOTYN Phase 3 trial for peripheral T-cell lymphoma

Allos Therapeutics, Inc. today announced the enrollment of the first patient in a Phase 3 randomized clinical trial (PDX-017) evaluating FOLOTYN in patients with previously undiagnosed peripheral T-cell lymphoma.

18 Aug 2011

Emergent commences TRU-016 Phase 1b/2 combination trial in relapsed indolent NHL

Emergent BioSolutions Inc. today announced the initiation of a Phase 1b/2 study (16011) of TRU-016 in combination with rituximab and bendamustine for patients with relapsed indolent non-Hodgkin's B-cell lymphomas, including follicular lymphoma, small lymphocytic lymphoma and marginal zone lymphoma.

17 Aug 2011

NCI, Pharmacyclics sign CRADA to develop PCI-32765 for blood cancers

Pharmacyclics, Inc. today announced the signing of a five-year Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to collaborate on the development of PCI-32765, a first-in-class, small molecule inhibitor of Bruton's tyrosine kinase (Btk) for the treatment of hematologic malignancies.

10 Aug 2011

Micromet second quarter total revenues increase to $7.1 million

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the second quarter and six months ended June 30, 2011.

4 Aug 2011

ImmunoGen revenues increase to $19.3 million for fiscal year 2011

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today reported financial results for the three-month period and fiscal year ended June 30, 2011.

4 Aug 2011

Yaupon seeks FDA marketing approval of mechlorethamine gel for mycosis fungoides

Yaupon Therapeutics, Inc., a privately held specialty pharmaceutical company, announced today the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its propriety gel formulation of mechlorethamine hydrochloride (mechlorethamine).

28 Jul 2011

EMA recommends orphan drug designation for 4SC's resminostat to treat HCC

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the European Medicines Agency (EMA) has recommended resminostat for designation as orphan medicinal product for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.

26 Jul 2011

Two genetic variations can identify children at higher risk of radiation-induced second cancers

A genome-wide association study published in the August issue of Nature Medicine has found two tiny genetic variations that can predict which patients with Hodgkin's lymphoma are most likely to develop radiation-induced second cancers years after treatment.

25 Jul 2011

Taller women more prone to cancer: Study

New research has shown that taller women could be more prone to suffering from cancer. The British study published online in the medical journal The Lancet on Thursday said cancer risk rose about 16% for every 4-inch rise in height. Increasing height heightened the chances of cancers of breast, ovary, womb, bowel, leukemia and malignant melanoma (skin cancer) the study found.

21 Jul 2011

Possible new drug targets for treating diffuse large B-cell lymphoma

Researchers at the University of Maryland School of Medicine have discovered a novel interaction between two proteins involved in regulating cell growth that could provide possible new drug targets for treating diffuse large B-cell lymphoma, the most common type of non-Hodgkin's lymphoma.

20 Jul 2011

FDA ODAC recommends approval of Seattle Genetics' ADCETRIS for Hodgkin lymphoma after ASCT

Seattle Genetics, Inc. today announced that the Oncologic Drugs Advisory Committee (ODAC) to the U.S. Food and Drug Administration (FDA) voted 10-0 to recommend that the FDA grant accelerated approval of ADCETRIS™ (brentuximab vedotin) for the treatment of patients with Hodgkin lymphoma who relapse after autologous stem cell transplant (ASCT).

15 Jul 2011

Seattle Genetics lymphoma drug gets FDA panel nod

Seattle Genetics Inc. has finally obtained the U.S. Food and Drugs Administration (FDA) nod for a second type of blood cancer drug. The FDA advisory committee voted 10-0 on Thursday to recommend accelerated approval of the drug, under the proposed trade name Adcetris, for anaplastic large cell lymphoma (ALCL). The panel earlier unanimously approved the drug for Hodgkin's lymphoma, another type of blood cancer.

14 Jul 2011

Blood cancer drug trial results questioned by FDA

U.S. drug reviewers might limit the use of a Seattle Genetics Inc’s experimental blood cancer drug due to the narrow scope of its clinical trials. According to papers released Tuesday by the Food and Drug Administration (FDA), it requests an advisory panel to consider the drug, under the proposed trade name Adcetris known chemically as brentuximab vedotin, for use in previously treated patients with Hodgkin's lymphoma and anaplastic large cell lymphoma (ALCL).

13 Jul 2011

Onconova, SymBio enter commercialization collaboration for rigosertib in Japan and Korea

Onconova Therapeutics, Inc., and SymBio Pharmaceuticals Limited announced today that they will collaborate to develop and commercialize rigosertib in Japan and Korea. Onconova is conducting late-stage clinical trials with rigosertib (ON 01910.Na) in the U.S., Europe and India for the treatment of Myelodysplastic Syndromes (MDS) and solid tumors.

8 Jul 2011

Nimbus Discovery closes $24 million Series A financing

Nimbus Discovery LLC, a biopharmaceutical company using state-of-the-art computational technology to discover novel medicines against exciting but previously inaccessible disease targets, today announced the close of a $24M Series A financing.

28 Jun 2011

EMA acceptance of brentuximab vedotin MAA triggers $5M milestone payment to Seattle Genetics

Seattle Genetics, Inc., today announced that it will receive a $5 million milestone payment under its brentuximab vedotin (ADCETRIS) collaboration with Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

27 Jun 2011

EMA accepts Millennium's MAA for ADCETRIS to treat lymphoma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for ADCETRIS for the treatment of relapsed or refractory Hodgkin lymphoma (HL) and relapsed or refractory systemic anaplastic large cell lymphoma.

27 Jun 2011

Millennium reports ongoing MLN8237 Phase II study results on non-Hodgkin lymphoma

Millennium: The Takeda Oncology Company today announced the presentation of results from an ongoing Phase II study of MLN8237, an investigational Aurora A kinase inhibitor, in patients with relapsed/refractory aggressive B-cell and T-cell non-Hodgkin lymphoma.

24 Jun 2011

FDA grants Orphan Drug Designation for Accentia's Revimmune to treat two autoimmune diseases

Accentia Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revimmune, the Company's proprietary system-of-care based on high-dose administration of Cytoxan, for the treatment of two autoimmune disease indications, systemic sclerosis and autoimmune hemolytic anemia.

24 Jun 2011

Spectrum announces various clinical studies on ZEVALIN at ICML 2011

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that various studies on ZEVALIN for Injection were presented at the 11th International Conference on Malignant Lymphoma (ICML), held June 15-18, 2011, in Lugano, Switzerland.

20 Jun 2011

Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Enrollment commences in Allos' FOLOTYN Phase 3 trial for peripheral T-cell lymphoma

Emergent commences TRU-016 Phase 1b/2 combination trial in relapsed indolent NHL

NCI, Pharmacyclics sign CRADA to develop PCI-32765 for blood cancers

Micromet second quarter total revenues increase to $7.1 million

ImmunoGen revenues increase to $19.3 million for fiscal year 2011

Yaupon seeks FDA marketing approval of mechlorethamine gel for mycosis fungoides

EMA recommends orphan drug designation for 4SC's resminostat to treat HCC

Two genetic variations can identify children at higher risk of radiation-induced second cancers

Taller women more prone to cancer: Study

Possible new drug targets for treating diffuse large B-cell lymphoma

FDA ODAC recommends approval of Seattle Genetics' ADCETRIS for Hodgkin lymphoma after ASCT

Seattle Genetics lymphoma drug gets FDA panel nod

Blood cancer drug trial results questioned by FDA

Onconova, SymBio enter commercialization collaboration for rigosertib in Japan and Korea

Nimbus Discovery closes $24 million Series A financing

EMA acceptance of brentuximab vedotin MAA triggers $5M milestone payment to Seattle Genetics

EMA accepts Millennium's MAA for ADCETRIS to treat lymphoma

Millennium reports ongoing MLN8237 Phase II study results on non-Hodgkin lymphoma

FDA grants Orphan Drug Designation for Accentia's Revimmune to treat two autoimmune diseases

Spectrum announces various clinical studies on ZEVALIN at ICML 2011

Everything you should know about lymphoma eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Everything you should know about lymphoma eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in